2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM‐002A), a first‐in‐class inhibitor of phosphatidylinositol‐3‐Phosphate 5‐Kinase (PIKfyve), in patients with relapsed or refractory B‐cell malignancies

      Blood.

      Read this article at

      ScienceOpen
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Medicine

          Comments

          Comment on this article